ImVisioN reports positive results from Phase I cat dander allergy trial

ImVisioN Therapeutics, a biopharmaceutical company, has obtained positive Phase I clinical results for its lead product, IVN201, an immunotherapeutic product for the treatment of cat dander allergy.

The study was conducted from August 2008 to March 2009 in a total of 20 patients with allergy to cat dander. The results demonstrated an excellent safety profile and exceptional tolerability in allergic patients, said ImVisioN.

In addition, the IVN201 (Cat-MAT) program showed the first signs of efficacy as measured by several clinical parameters. The double-blind, placebo-controlled clinical study was conducted at the University Hospital in Zurich, Switzerland.

Based on these results, ImVisioN plans to close a series B financing round by mid-2009, which will be used to fund Phase II clinical studies of Cat-MAT and to start clinical trials with Birch-MAT to treat birch pollen allergy and Mite-MAT to treat house dust-mite allergy, respectively.

Martin Steiner, CEO of ImVisioN, said: We are delighted to report that the results of our first human clinical study with IVN201 have demonstrated an outstanding safety profile together with immunological effects and indications of clinical efficacy. These results are remarkable for a first-in-man clinical study and we are now very keen to begin a subsequent Phase II trial with a larger number of patients.